Magnetic Graphene Oxide and Graphene Nanoribbon Nanoparticles

A nanoparticle based MRI CA consisting of graphene nanoparticles intercalated and coordinated with trace amounts of manganese. Background: MRI contrast agents are routinely employed during MRI examinations to improve diagnostic confidence. Gadolinium (Gd)-based MRI-CAs dominate the market and are considered the “gold standard.” However, in patients with advanced renal failure, some of of these Gd-based CAs have induced a disease known as nephrogenic systemic fibrosis (NSF); a rare but severely debilitating condition that hardens and thickens the skin that results in joint contractures, restricted joint mobility and extreme pain. Furthermore, the heart, lungs and liver can be affected by Gd CAs sometimes resulting in death. Consequently, FDA has restricted their clinical use of all Gadolinium based CA in patients with advanced renal failure. Technology Overview: Researchers at Stony Brook University have developed a high performance nanoparticle based MRI CA consisting out of high quality graphene nanoparticles intercalated and coordinated with trace amounts of manganese. in‑vivo efficacy studies indicate that equivalent MRI performance can be achieved at substantially lower dosages than currently used CAs. This novel CA has also shown a good safety pharmacology profile including no nephrotoxicity at therapeutic doses and increased in-vivo circulation time, suggesting the possibility for its use as organ‑specific CA and an extended-residence –intravascular blood pool agent to image renal arteries.


Stage of Development

Preclinical Advantages: Easily scalable, efficient, high yielding, and amenable to suitable chemical functionalization for incorporation of other important metal atoms. High potential for development of multimodal imaging contrast agents for medical diagnostic modalities. Applications: - MRI contrast agents  - Contrast agents for existing and newly emerging multimodal imagingtechnologies as well as experimental forms of multimodal imaging. Intellectual Property Summary: Patent application submitted Stage of Development: PCT Publication No. WO 2012-154677. US9,713,650; CN201280033576.7; JP6139511 Licensing Potential: Licensing,Development partner,Commercial partner Licensing Status: Available for license. Stony Brook University seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. #8288 Additional Information: contrast,contrast agent,nanoparticle,diagnostic,renal,renal failure,graphene,manganese,pharmacology,image,artery,organ,imaging,imaging contrast agent,nanoparticle diagnostic,nano-particle,contrast media,imaging agent,imaging agents,magnetic resonance imaging,diagnostic imaging,medical imaging,graphene application,graphene oxide,graphene nanoribbons,magnetic nanoparticle,magnetic,organ imaging,arterial,medical diagnosis,medical diagnostics,nano-graphene ribbons,kidney,chemicals,nephrology Please note, header image is purely illustrative. Source: Hellerhoff, Wikimedia Commons, CC BY-SA 3.0.

Patent Information:
Technology/Start-up ID: